{"organizations": [], "uuid": "f7c8e0d137e541d07629fe2bd413798b120e6329", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-bluebird-bio-and-celgene-corporati/brief-bluebird-bio-and-celgene-corporation-to-co-develop-anti-bcma-car-t-cell-therapy-bb2121-in-the-u-s-idUSFWN1RA0JJ", "country": "US", "domain_rank": 408, "title": "BRIEF-Bluebird Bio And Celgene Corporation To Co-Develop Anti-Bcma Car T Cell Therapy Bb2121 In The U.S.", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-28T15:16:00.000+03:00", "replies_count": 0, "uuid": "f7c8e0d137e541d07629fe2bd413798b120e6329"}, "author": "", "url": "https://www.reuters.com/article/brief-bluebird-bio-and-celgene-corporati/brief-bluebird-bio-and-celgene-corporation-to-co-develop-anti-bcma-car-t-cell-therapy-bb2121-in-the-u-s-idUSFWN1RA0JJ", "ord_in_thread": 0, "title": "BRIEF-Bluebird Bio And Celgene Corporation To Co-Develop Anti-Bcma Car T Cell Therapy Bb2121 In The U.S.", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "celgene corporation to co-develop", "sentiment": "negative"}, {"name": "min read    bluebird bio inc", "sentiment": "none"}, {"name": "united", "sentiment": "none"}, {"name": "u.s. reuters", "sentiment": "none"}, {"name": "celgene", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 20 PM / in 2 minutes BRIEF-Bluebird Bio And Celgene Corporation To Co-Develop Anti-Bcma Car T Cell Therapy Bb2121 In The U.S. Reuters Staff 1 Min Read \n  Bluebird Bio Inc: \n* BLUEBIRD BIO AND CELGENE CORPORATION ENTER INTO AGREEMENT TO CO-DEVELOP AND CO-PROMOTE ANTI-BCMA CAR T CELL THERAPY BB2121 IN THE UNITED STATES \n* ‍BLUEBIRD AND CELGENE WILL SHARE 50% OF U.S. COSTS AND PROFITS​ \n* ‍BLUEBIRD TO RECEIVE MILESTONES AND ROYALTIES ON EX-U.S. SALES​  ", "external_links": [], "published": "2018-03-28T15:16:00.000+03:00", "crawled": "2018-03-28T15:34:56.038+03:00", "highlightTitle": ""}